Marilyn Huestis

TitleInstructor CHP
InstitutionThomas Jefferson University
DepartmentInstitute for Emerging Hlth Pr
Address1020 Locust St.
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wade NE, Wallace AL, Huestis MA, Lisdahl KM, Sullivan RM, Tapert SF. Cannabis use and neurocognitive performance at 13-14 Years-Old: Optimizing assessment with hair toxicology in the Adolescent brain cognitive development (ABCD) study. Addict Behav. 2024 Mar; 150:107930. PMID: 38091780.
      Citations:    
    2. Cliburn KD, Kemp PM, Huestis MA, Wagner JR, Payton M, Liu L, Liang Y, Maxwell LK. Time- and Temperature-Dependent Postmortem ?9-Tetrahydrocannabinol Concentration Changes in Rabbits following Controlled Inhaled Cannabis Administration. J Anal Toxicol. 2023 Sep 27. PMID: 37758448.
      Citations:    
    3. Marcotte TD, Umlauf A, Grelotti DJ, Sones EG, Mastropietro KF, Suhandynata RT, Huestis MA, Grant I, Fitzgerald RL. Evaluation of Field Sobriety Tests for Identifying Drivers Under the Influence of Cannabis: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Sep 01; 80(9):914-923. PMID: 37531115.
      Citations:    
    4. Lo Faro AF, Berardinelli D, Cassano T, Dendramis G, Montanari E, Montana A, Berretta P, Zaami S, Busard? FP, Huestis MA. New Psychoactive Substances Intoxications and Fatalities during the COVID-19 Epidemic. Biology (Basel). 2023 Feb 08; 12(2). PMID: 36829550.
      Citations:    
    5. Carlier J, Malaca S, Huestis MA, Tagliabracci A, Tini A, Busard? FP. Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations. Expert Opin Drug Metab Toxicol. 2022 Dec; 18(12):831-840. PMID: 36609205.
      Citations:    
    6. Torrens A, Ruiz CM, Martinez MX, Tagne AM, Roy P, Grimes D, Ahmed F, Lallai V, Inshishian V, Bautista M, Chen YC, Huestis MA, Das A, Fowler CD, Mahler SV, Piomelli D. Nasal accumulation and metabolism of ?9-tetrahydrocannabinol following aerosol ('vaping') administration in an adolescent rat model. Pharmacol Res. 2023 01; 187:106600. PMID: 36481259.
      Citations:    
    7. Poyatos L, Lo Faro AF, Berardinelli D, Sprega G, Malaca S, Pichini S, Huestis MA, Papaseit E, P?rez-Ma?? C, Busard? FP, Farr? M. Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans. Int J Mol Sci. 2022 Nov 23; 23(23). PMID: 36498963.
      Citations:    
    8. Di Trana A, Berardinelli D, Montanari E, Berretta P, Basile G, Huestis MA, Busard? FP. Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. Int J Mol Sci. 2022 Nov 23; 23(23). PMID: 36498947.
      Citations:    
    9. Ahmed F, Torrens A, Mahler SV, Ferlenghi F, Huestis MA, Piomelli D. A Sensitive Ultrahigh-Performance Liquid Chromatography/Tandem Mass Spectrometry Method for the Simultaneous Analysis of Phytocannabinoids and Endocannabinoids in Plasma and Brain. Cannabis Cannabinoid Res. 2022 Nov 11. PMID: 36367975.
      Citations:    
    10. Pigliasco F, Malaca S, Lo Faro AF, Tini A, Cangemi G, Cafaro A, Barco S, Riva A, Pisati A, Amadori E, Striano P, Tagliabracci A, Huestis MA, Busard? FP. Cannabidiol, ?9-tetrahydrocannabinol, and metabolites in human blood by volumetric absorptive microsampling and LC-MS/MS following controlled administration in epilepsy patients. Front Pharmacol. 2022; 13:1038754. PMID: 36353497.
      Citations:    
    11. La Maida N, Di Giorgi A, Pichini S, Busard? FP, Huestis MA. Recent challenges and trends in forensic analysis: ?9-THC isomers pharmacology, toxicology and analysis. J Pharm Biomed Anal. 2022 Oct 25; 220:114987. PMID: 35985136.
      Citations:    
    12. Malaca S, Huestis MA, Lattanzio L, Marsella LT, Tagliabracci A, Carlier J, Busard? FP. Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry. Metabolites. 2022 Jul 29; 12(8). PMID: 36005577.
      Citations:    
    13. Wickens CM, Wright M, Mann RE, Brands B, Di Ciano P, Stoduto G, Fares A, Matheson J, George TP, Rehm J, Shuper PA, Sproule B, Samohkvalov A, Huestis MA, Le Foll B. Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2022 08 30; 118:110570. PMID: 35551928.
      Citations:    
    14. Henningfield JE, Wang DW, Huestis MA. Kratom Abuse Potential 2021: An Updated Eight Factor Analysis. Front Pharmacol. 2021; 12:775073. PMID: 35197848.
      Citations:    
    15. Cliburn KD, Huestis MA, Wagner JR, Kemp PM. Cannabinoid distribution in fatally-injured pilots' postmortem fluids and tissues. Forensic Sci Int. 2021 Dec; 329:111075. PMID: 34749280.
      Citations:    
    16. Rodrigues TB, Morais DR, Gianvecchio VAP, Aquino EM, Cunha RL, Huestis MA, Costa JL. Development and Validation of a Method for Quantification of 28 Psychotropic Drugs in Postmortem Blood Samples by Modified Micro-QuEChERS and LC-MS-MS. J Anal Toxicol. 2021 Aug 14; 45(7):644-656. PMID: 32991709.
      Citations:    
    17. da Cunha KF, Oliveira KD, Cardoso MS, Arantes ACF, Coser PHP, Lima LN, Maluf ACS, Comis MAC, Huestis MA, Costa JL. Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties. Drug Alcohol Depend. 2021 10 01; 227:108962. PMID: 34461412.
      Citations:    
    18. Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busard? FP. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals (Basel). 2021 Jun 11; 14(6). PMID: 34208284.
      Citations:    
    19. La Maida N, Di Trana A, Giorgetti R, Tagliabracci A, Busard? FP, Huestis MA. A Review of Synthetic Cathinone-Related Fatalities From 2017 to 2020. Ther Drug Monit. 2021 02 01; 43(1):52-68. PMID: 32881779.
      Citations:    
    20. Carlier J, Diao X, Giorgetti R, Busard? FP, Huestis MA. Pyrrolidinyl Synthetic Cathinones a-PHP and 4F-a-PVP Metabolite Profiling Using Human Hepatocyte Incubations. Int J Mol Sci. 2020 Dec 28; 22(1). PMID: 33379373.
      Citations:    
    21. Mareck U, Fussh?ller G, Geyer H, Huestis MA, Scheiff AB, Thevis M. Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. Drug Test Anal. 2021 Mar; 13(3):539-549. PMID: 33125823.
      Citations:    
    22. Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busard? FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. Int J Mol Sci. 2020 Dec 04; 21(23). PMID: 33291798.
      Citations:    
    23. da Cunha KF, Oliveira KD, Huestis MA, Costa JL. Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC-MS-MS. J Anal Toxicol. 2020 Oct 12; 44(7):697-707. PMID: 32685960.
      Citations:    
    24. Sofalvi S, Lavins ES, Kaspar CK, Michel HM, Mitchell-Mata CL, Huestis MA, Apollonio LG. Development and Validation of an LC-MS-MS Method for the Detection of 40 Benzodiazepines and Three Z-Drugs in Blood and Urine by Solid-Phase Extraction. J Anal Toxicol. 2020 Oct 12; 44(7):708-717. PMID: 32808043.
      Citations:    
    25. Huestis MA, Sempio C, Newmeyer MN, Andersson M, Barnes AJ, Abulseoud OA, Blount BC, Schroeder J, Smith ML. Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. J Anal Toxicol. 2020 Oct 12; 44(7):651-660. PMID: 32369162.
      Citations:    
    26. Ruiz CM, Torrens A, Castillo E, Perrone CR, Cevallos J, Inshishian VC, Harder EV, Justeson DN, Huestis MA, Swarup V, Piomelli D, Mahler SV. Pharmacokinetic, behavioral, and brain activity effects of ?9-tetrahydrocannabinol in adolescent male and female rats. Neuropsychopharmacology. 2021 04; 46(5):959-969. PMID: 32927465.
      Citations:    
    27. Karschner EL, Swortwood-Gates MJ, Huestis MA. Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. Clin Chem. 2020 07 01; 66(7):888-914. PMID: 32628766.
      Citations:    
    28. Eiden RD, Shisler S, Granger DA, Schuetze P, Colangelo J, Huestis MA. Prenatal Tobacco and Cannabis Exposure: Associations with Cortisol Reactivity in Early School Age Children. Int J Behav Med. 2020 Jun; 27(3):343-356. PMID: 32291618.
      Citations:    
    29. Matheson J, Mann RE, Sproule B, Huestis MA, Wickens CM, Stoduto G, George TP, Rehm J, Le Foll B, Brands B. Acute and residual mood and cognitive performance of young adults following smoked cannabis. Pharmacol Biochem Behav. 2020 07; 194:172937. PMID: 32360692.
      Citations:    
    30. Torrens A, Vozella V, Huff H, McNeil B, Ahmed F, Ghidini A, Mahler SV, Huestis MA, Das A, Piomelli D. Comparative Pharmacokinetics of ?9-Tetrahydrocannabinol in Adolescent and Adult Male Mice. J Pharmacol Exp Ther. 2020 07; 374(1):151-160. PMID: 32345621.
      Citations:    
    31. Hubbard JA, Smith BE, Sobolesky PM, Kim S, Hoffman MA, Stone J, Huestis MA, Grelotti DJ, Grant I, Marcotte TD, Fitzgerald RL. Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath. Clin Chem Lab Med. 2020 04 28; 58(5):673-681. PMID: 31527291.
      Citations:    
    32. Pacifici R, Pichini S, Pellegrini M, Rotolo MC, Giorgetti R, Tagliabracci A, Busard? FP, Huestis MA. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis". Clin Chem Lab Med. 2020 04 28; 58(5):682-689. PMID: 30956228.
      Citations:    
    33. Carlier J, Huestis MA, Zaami S, Pichini S, Busard? FP. Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. Ther Drug Monit. 2020 04; 42(2):194-204. PMID: 32195988.
      Citations:    
    34. Carlier J, La Maida N, Di Trana A, Huestis MA, Pichini S, Busard? FP. Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. Ther Drug Monit. 2020 04; 42(2):205-221. PMID: 31809406.
      Citations:    
    35. Di Trana A, La Maida N, Tittarelli R, Huestis MA, Pichini S, Busard? FP, Carlier J. Monitoring Prenatal Exposure to Buprenorphine and Methadone. Ther Drug Monit. 2020 04; 42(2):181-193. PMID: 31425444.
      Citations:    
    36. Sempio C, Huestis MA, Mikulich-Gilbertson SK, Klawitter J, Christians U, Henthorn TK. Population pharmacokinetic modeling of plasma ?9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. Br J Clin Pharmacol. 2020 03; 86(3):611-619. PMID: 31747464.
      Citations:    
    37. Brands B, Mann RE, Wickens CM, Sproule B, Stoduto G, Sayer GS, Burston J, Pan JF, Matheson J, Stefan C, George TP, Huestis MA, Rehm J, Le Foll B. Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. Drug Alcohol Depend. 2019 12 01; 205:107641. PMID: 31678833.
      Citations:    
    38. Huestis MA, Blount BC, Milan DF, Newmeyer MN, Schroeder J, Smith ML. Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. Drug Test Anal. 2019 Jul; 11(7):968-975. PMID: 30756523.
      Citations:    
    39. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busard? FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019; 17(10):974-989. PMID: 31161980.
      Citations:    
    40. Carlier J, Wohlfarth A, Salmeron BD, Scheidweiler KB, Huestis MA, Baumann MH. Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. J Pharmacol Exp Ther. 2018 12; 367(3):543-550. PMID: 30266766.
      Citations:    
    41. Carlier J, Diao X, Huestis MA. Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. J Pharm Biomed Anal. 2018 Aug 05; 157:27-35. PMID: 29754040.
      Citations:    
    42. Huestis MA, Smith ML. Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. Trends Mol Med. 2018 02; 24(2):156-172. PMID: 29398403.
      Citations:    
    43. Jacobus J, Squeglia LM, Escobar S, McKenna BM, Hernandez MM, Bagot KS, Taylor CT, Huestis MA. Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users. Psychopharmacology (Berl). 2017 Dec; 234(23-24):3431-3442. PMID: 28900686.
      Citations:    
    44. Bouhlal S, Ellefsen KN, Sheskier MB, Singley E, Pirard S, Gorelick DA, Huestis MA, Leggio L. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug Alcohol Depend. 2017 11 01; 180:68-75. PMID: 28881319.
      Citations:    
    45. Diao X, Carlier J, Zhu M, Huestis MA. Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clin Chem. 2017 Nov; 63(11):1753-1763. PMID: 28821542.
      Citations:    
    46. Sempio C, Scheidweiler KB, Barnes AJ, Huestis MA. Optimization of recombinant ?-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. Drug Test Anal. 2018 Mar; 10(3):518-529. PMID: 28815938.
      Citations:    
    47. Carlier J, Diao X, Wohlfarth A, Scheidweiler K, Huestis MA. In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Curr Neuropharmacol. 2017 Jul; 15(5):682-691. PMID: 29403341.
      Citations:    
    48. Huestis MA, Brandt SD, Rana S, Auw?rter V, Baumann MH. Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. Clin Chem. 2017 10; 63(10):1564-1569. PMID: 28667187.
      Citations:    
    49. Abulseoud OA, Zuccoli ML, Zhang L, Barnes A, Huestis MA, Lin DT. The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. Eur Neuropsychopharmacol. 2017 07; 27(7):679-690. PMID: 28456476.
      Citations:    
    50. Carlier J, Diao X, Scheidweiler KB, Huestis MA. Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clin Chem. 2017 05; 63(5):1008-1021. PMID: 28302730.
      Citations:    
    51. Newmeyer MN, Swortwood MJ, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting ?9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. Clin Chem. 2017 03; 63(3):647-662. PMID: 28188235.
      Citations:    
    52. Carlier J, Diao X, Sempio C, Huestis MA. Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS J. 2017 03; 19(2):568-577. PMID: 28070717.
      Citations:    
    53. Carlier J, Diao X, Wohlfarth A, Scheidweiler K, Huestis MA. In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Curr Neuropharmacol. 2016 Nov 08. PMID: 27829332.
      Citations:    
    54. Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Test Anal. 2017 Jun; 9(6):905-915. PMID: 27647820.
      Citations:    
    55. Scheidweiler KB, Andersson M, Swortwood MJ, Sempio C, Huestis MA. Long-term stability of cannabinoids in oral fluid after controlled cannabis administration. Drug Test Anal. 2017 Jan; 9(1):143-147. PMID: 27539096.
      Citations:    
    56. Wohlfarth A, Roman M, Andersson M, Kugelberg FC, Diao X, Carlier J, Eriksson C, Wu X, Konradsson P, Josefsson M, Huestis MA, Kronstrand R. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry. Drug Test Anal. 2017 May; 9(5):680-698. PMID: 27448631.
      Citations:    
    57. Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA. In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol. 2017 Jan; 35(1):20-32. PMID: 28286577.
      Citations:    
    58. Eriksen GS, Andersen JM, Boix F, Bergh MS, Vindenes V, Rice KC, Huestis MA, M?rland J. Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice. J Pharmacol Exp Ther. 2016 08; 358(2):209-15. PMID: 27278234.
      Citations:    
    59. Scheidweiler KB, Newmeyer MN, Barnes AJ, Huestis MA. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2016 Jul 01; 1453:34-42. PMID: 27236483.
      Citations:    
    60. Carlier J, Scheidweiler KB, Wohlfarth A, Salmeron BD, Baumann MH, Huestis MA. Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2016 Jun 17; 1451:97-106. PMID: 27208987.
      Citations:    
    61. Boileau I, Mansouri E, Williams B, Le Foll B, Rusjan P, Mizrahi R, Tyndale RF, Huestis MA, Payer DE, Wilson AA, Houle S, Kish SJ, Tong J. Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB. Biol Psychiatry. 2016 11 01; 80(9):691-701. PMID: 27345297.
      Citations:    
    62. Hartman RL, Richman JE, Hayes CE, Huestis MA. Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. Accid Anal Prev. 2016 Jul; 92:219-29. PMID: 27107471.
      Citations:    
    63. Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, Huestis MA. Effect of Blood Collection Time on Measured ?9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. Clin Chem. 2016 Feb; 62(2):367-77. PMID: 26823611.
      Citations:    
    64. And?s HT, Enger A, ?iestad ?M, Vindenes V, Christophersen AS, Huestis MA, ?iestad EL. Extended Detection of Amphetamine and Methamphetamine in Oral Fluid. Ther Drug Monit. 2016 Feb; 38(1):114-9. PMID: 26402425.
      Citations:    
    65. Swortwood MJ, Carlier J, Ellefsen KN, Wohlfarth A, Diao X, Concheiro-Guisan M, Kronstrand R, Huestis MA. In vitro, in vivo and in silico metabolic profiling of a-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis. 2016; 8(1):65-82. PMID: 26648097.
      Citations:    
    66. Huestis MA. Cannabis-impaired driving: a public health and safety concern. Clin Chem. 2015 Oct; 61(10):1223-5. PMID: 26283691.
      Citations:    
    67. Ellefsen KN, Wohlfarth A, Swortwood MJ, Diao X, Concheiro M, Huestis MA. 4-Methoxy-a-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicol. 2016; 34:61-75. PMID: 26793277.
      Citations:    
    68. Himes SK, Wu JW, Jacobson DL, Tassiopoulos K, Hazra R, Kacanek D, Van Dyke RB, Rich KC, Siberry GK, Huestis MA. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children. Pediatr Infect Dis J. 2015 Aug; 34(8):851-7. PMID: 25961889.
      Citations:    
    69. Karschner EL, Swortwood MJ, Hirvonen J, Goodwin RS, Bosker WM, Ramaekers JG, Huestis MA. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. Drug Test Anal. 2016 Jul; 8(7):682-9. PMID: 26097154.
      Citations:    
    70. Himes SK, Huo Y, Siberry GK, Williams PL, Rice ML, Sirois PA, Frederick T, Hazra R, Huestis MA. Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):178-86. PMID: 26009830.
      Citations:    
    71. Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, Winkel G, Sinha R, Jutras-Aswad D, Huestis MA, Hurd YL. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015 May-Jun; 9(3):204-10. PMID: 25748562.
      Citations:    
    72. Castaneto MS, Wohlfarth A, Desrosiers NA, Hartman RL, Gorelick DA, Huestis MA. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev. 2015 May; 47(2):124-74. PMID: 25853390.
      Citations:    
    73. Wohlfarth A, Scheidweiler KB, Castaneto M, Gandhi AS, Desrosiers NA, Klette KL, Martin TM, Huestis MA. Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clin Chem Lab Med. 2015 Feb; 53(3):423-34. PMID: 25263309.
      Citations:    
    74. Smith ML, Nichols DC, Underwood P, Fuller Z, Moser MA, Flegel R, Gorelick DA, Newmeyer MN, Concheiro M, Huestis MA. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. J Anal Toxicol. 2014 Oct; 38(8):524-7. PMID: 25217541.
      Citations:    
    75. Castaneto MS, Scheidweiler KB, Gandhi A, Wohlfarth A, Klette KL, Martin TM, Huestis MA. Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal. 2015 Jun; 7(6):483-93. PMID: 25231213.
      Citations:    
    76. Scheidweiler KB, Jarvis MJ, Huestis MA. Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem. 2015 Jan; 407(3):883-97. PMID: 25224637.
      Citations:    
    77. Lee D, Vandrey R, Mendu DR, Murray JA, Barnes AJ, Huestis MA. Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. Drug Test Anal. 2015 Jun; 7(6):494-501. PMID: 25220020.
      Citations:    
    78. Spinelli E, Barnes AJ, Young S, Castaneto MS, Martin TM, Klette KL, Huestis MA. Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. Drug Test Anal. 2015 Jun; 7(6):467-74. PMID: 25167963.
      Citations:    
    79. Ellefsen KN, Concheiro M, Beck O, Gorelick DA, Pirard S, Huestis MA. Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. Anal Bioanal Chem. 2014 Oct; 406(25):6213-23. PMID: 25129634.
      Citations:    
    80. Himes SK, LaGasse LL, Derauf C, Newman E, Smith LM, Arria AM, Della Grotta SA, Dansereau LM, Abar B, Neal CR, Lester BM, Huestis MA. Risk of neurobehavioral disinhibition in prenatal methamphetamine-exposed young children with positive hair toxicology results. Ther Drug Monit. 2014 Aug; 36(4):535-43. PMID: 24518561.
      Citations:    
    81. Newmeyer MN, Concheiro M, Huestis MA. Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent. J Chromatogr A. 2014 Sep 05; 1358:68-74. PMID: 25065924.
      Citations:    
    82. Anizan S, Bergamaschi MM, Barnes AJ, Milman G, Desrosiers N, Lee D, Gorelick DA, Huestis MA. Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. Drug Test Anal. 2015 Feb; 7(2):114-20. PMID: 24995604.
      Citations:    
    83. Smith ML, Nichols DC, Underwood P, Fuller Z, Moser MA, LoDico C, Gorelick DA, Newmeyer MN, Concheiro M, Huestis MA. Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. Forensic Sci Int. 2014 Aug; 241:87-90. PMID: 24887324.
      Citations:    
    84. Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, Huestis MA. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict. 2014 May-Jun; 23(3):234-42. PMID: 24724880.
      Citations:    
    85. Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit. 2014 Apr; 36(2):218-24. PMID: 24067260.
      Citations:    
    86. Barnes AJ, Scheidweiler KB, Huestis MA. Quantification of 11-nor-9-carboxy-d9-tetrahydrocannabinol in human oral fluid by gas chromatography-tandem mass spectrometry. Ther Drug Monit. 2014 Apr; 36(2):225-33. PMID: 24622724.
      Citations:    
    87. Newmeyer MN, Desrosiers NA, Lee D, Mendu DR, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal. 2014 Oct; 6(10):1002-10. PMID: 24652685.
      Citations:    
    88. Himes SK, Concheiro M, Scheidweiler KB, Huestis MA. Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. Anal Bioanal Chem. 2014 Mar; 406(7):1945-55. PMID: 24408304.
      Citations:    
    89. Castaneto MS, Desrosiers NA, Ellefsen K, Anizan S, Martin TM, Klette KL, Huestis MA. Method validation of the biochip array technology for synthetic cannabinoids detection in urine. Bioanalysis. 2014; 6(21):2919-30. PMID: 25486237.
      Citations:    
    90. Scheidweiler KB, Huestis MA. Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2014 Jan 31; 1327:105-17. PMID: 24418231.
      Citations:    
    91. Koola MM, Gorelick DA, McMahon RP, Liu F, Huestis MA, Linthicum J, Feldman SM, Warren KR, Wehring HJ, Kelly DL. Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. Schizophr Res. 2014 Jan; 152(1):315-6. PMID: 24333005.
      Citations:    
    92. Bergamaschi MM, Queiroz RH, Chagas MH, Linares IM, Arrais KC, de Oliveira DC, Queiroz ME, Nardi AE, Huestis MA, Hallak JE, Zuardi AW, Moreira FA, Crippa JA. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Hum Psychopharmacol. 2014 Jan; 29(1):94-9. PMID: 24424711.
      Citations:    
    93. Desrosiers NA, Lee D, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Anal Bioanal Chem. 2014 Jan; 406(3):785-92. PMID: 24292435.
      Citations:    
    94. Castaneto MS, Barnes AJ, Scheidweiler KB, Schaffer M, Rogers KK, Stewart D, Huestis MA. Identifying methamphetamine exposure in children. Ther Drug Monit. 2013 Dec; 35(6):823-30. PMID: 24263642.
      Citations:    
    95. Hartman RL, Desrosiers NA, Barnes AJ, Yun K, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA. 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. Anal Bioanal Chem. 2014 Jan; 406(2):587-99. PMID: 24232751.
      Citations:    
    96. Desrosiers NA, Lee D, Concheiro-Guisan M, Scheidweiler KB, Gorelick DA, Huestis MA. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? Clin Chem. 2014 Feb; 60(2):361-72. PMID: 24185550.
      Citations:    
    97. Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos. 2014 Jan; 42(1):119-25. PMID: 24141857.
      Citations:    
    98. Lee D, Huestis MA. Current knowledge on cannabinoids in oral fluid. Drug Test Anal. 2014 Jan-Feb; 6(1-2):88-111. PMID: 23983217.
      Citations:    
    99. Anizan S, Milman G, Desrosiers N, Barnes AJ, Gorelick DA, Huestis MA. Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Anal Bioanal Chem. 2013 Oct; 405(26):8451-61. PMID: 23954944.
      Citations:    
    100. Scheidweiler KB, Himes SK, Chen X, Liu HF, Huestis MA. 11-Nor-9-carboxy-?9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2013 Jul; 405(18):6019-27. PMID: 23681203.
      Citations:    
    101. Concheiro M, Lee D, Lendoiro E, Huestis MA. Simultaneous quantification of ?(9)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry. J Chromatogr A. 2013 Jul 05; 1297:123-30. PMID: 23726246.
      Citations:    
    102. Wu M, Lagasse LL, Wouldes TA, Arria AM, Wilcox T, Derauf C, Newman E, Shah R, Smith LM, Neal CR, Huestis MA, Dellagrotta S, Lester BM. Predictors of inadequate prenatal care in methamphetamine-using mothers in New Zealand and the United States. Matern Child Health J. 2013 Apr; 17(3):566-75. PMID: 22588827.
      Citations:    
    103. Scheidweiler KB, Schwope DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. Clin Chem. 2013 Jul; 59(7):1108-17. PMID: 23519966.
      Citations:    
    104. Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem. 2013 Apr 02; 85(7):3730-8. PMID: 23458260.
      Citations:    
    105. Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013 Mar; 59(3):519-26. PMID: 23449702.
      Citations:    
    106. Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug Alcohol Depend. 2013 Jun 01; 130(1-3):68-76. PMID: 23146820.
      Citations:    
    107. Desrosiers NA, Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA. On-site test for cannabinoids in oral fluid. Clin Chem. 2012 Oct; 58(10):1418-25. PMID: 22912396.
      Citations:    
    108. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and physiological effects and whole blood ??-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol. 2012 Jul; 36(6):405-12. PMID: 22589524.
      Citations:    
    109. Lee D, Milman G, Schwope DM, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin Chem. 2012 Jul; 58(7):1101-9. PMID: 22532594.
      Citations:    
    110. Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Predictive model accuracy in estimating last ?9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012 Oct 01; 125(3):313-9. PMID: 22464363.
      Citations:    
    111. LaGasse LL, Derauf C, Smith LM, Newman E, Shah R, Neal C, Arria A, Huestis MA, DellaGrotta S, Lin H, Dansereau LM, Lester BM. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics. 2012 Apr; 129(4):681-8. PMID: 22430455.
      Citations:    
    112. Polettini A, Cone EJ, Gorelick DA, Huestis MA. Incorporation of methamphetamine and amphetamine in human hair following controlled oral methamphetamine administration. Anal Chim Acta. 2012 May 13; 726:35-43. PMID: 22541011.
      Citations:    
    113. Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem. 2012 Apr; 58(4):748-56. PMID: 22273566.
      Citations:    
    114. Milman G, Schwope DM, Gorelick DA, Huestis MA. Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin Chim Acta. 2012 Apr 11; 413(7-8):765-70. PMID: 22285315.
      Citations:    
    115. Schwaninger AE, Meyer MR, Barnes AJ, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA, Maurer HH. Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. Clin Chem. 2011 Dec; 57(12):1748-56. PMID: 21980168.
      Citations:    
    116. Schwaninger AE, Meyer MR, Barnes AJ, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA, Maurer HH. Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. Biochem Pharmacol. 2012 Jan 01; 83(1):131-8. PMID: 21983032.
      Citations:    
    117. Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral ?(9)-tetrahydrocannabinol administration. Clin Chem. 2011 Nov; 57(11):1597-606. PMID: 21875944.
      Citations:    
    118. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem. 2011 Oct; 57(10):1406-14. PMID: 21836075.
      Citations:    
    119. Holland MG, Schwope DM, Stoppacher R, Gillen SB, Huestis MA. Postmortem redistribution of ?9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Sci Int. 2011 Oct 10; 212(1-3):247-51. PMID: 21764230.
      Citations:    
    120. Schwaninger AE, Meyer MR, Huestis MA, Maurer HH. Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. J Mass Spectrom. 2011 Jul; 46(7):603-14. PMID: 21656610.
      Citations:    
    121. Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem. 2011 Aug; 57(8):1127-36. PMID: 21677094.
      Citations:    
    122. Milman G, Barnes AJ, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. Anal Bioanal Chem. 2011 Aug; 401(2):599-607. PMID: 21637933.
      Citations:    
    123. Huestis MA, Verstraete A, Kwong TC, Morland J, Vincent MJ, de la Torre R. Oral fluid testing: promises and pitfalls. Clin Chem. 2011 Jun; 57(6):805-10. PMID: 21350039.
      Citations:    
    124. Schwilke EW, Gullberg RG, Darwin WD, Chiang CN, Cadet JL, Gorelick DA, Pope HG, Huestis MA. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction. 2011 Mar; 106(3):499-506. PMID: 21134021.
      Citations:    
    125. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011 Jan; 57(1):66-75. PMID: 21078841.
      Citations:    
    126. Delaney-Black V, Chiodo LM, Hannigan JH, Greenwald MK, Janisse J, Patterson G, Huestis MA, Ager J, Sokol RJ. Just say "I don't": lack of concordance between teen report and biological measures of drug use. Pediatrics. 2010 Nov; 126(5):887-93. PMID: 20974792.
      Citations:    
    127. Scheidweiler KB, Spargo EA, Kelly TL, Cone EJ, Barnes AJ, Huestis MA. Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. Ther Drug Monit. 2010 Oct; 32(5):628-37. PMID: 20814350.
      Citations:    
    128. Gray TR, Eiden RD, Leonard KE, Connors GJ, Shisler S, Huestis MA. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem. 2010 Sep; 56(9):1442-50. PMID: 20628142.
      Citations:    
    129. Milman G, Barnes AJ, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem. 2010 Aug; 56(8):1261-9. PMID: 20530732.
      Citations:    
    130. Karschner EL, Barnes AJ, Lowe RH, Scheidweiler KB, Huestis MA. Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Anal Bioanal Chem. 2010 May; 397(2):603-11. PMID: 20306180.
      Citations:    
    131. Smith ML, Shimomura E, Paul BD, Cone EJ, Darwin WD, Huestis MA. Urinary excretion of ecgonine and five other cocaine metabolites following controlled oral, intravenous, intranasal, and smoked administration of cocaine. J Anal Toxicol. 2010 Mar; 34(2):57-63. PMID: 20223096.
      Citations:    
    132. Gray TR, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, Arria AM, Della Grotta SA, Strauss A, Haning WF, Lester BM, Huestis MA. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit. 2009 Dec; 31(6):769-75. PMID: 19935364.
      Citations:    
    133. Westin AA, Huestis MA, Aarstad K, Spigset O. Short communication: Urinary excretion of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol in a pregnant woman following heavy, chronic cannabis use. J Anal Toxicol. 2009 Nov-Dec; 33(9):610-4. PMID: 20040136.
      Citations:    
    134. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem. 2009 Dec; 55(12):2180-9. PMID: 19833841.
      Citations:    
    135. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, Cadet JL, Huestis MA. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction. 2009 Dec; 104(12):2041-8. PMID: 19804462.
      Citations:    
    136. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, Cadet JL, Huestis MA. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol. 2009 Oct; 33(8):469-77. PMID: 19874654.
      Citations:    
    137. Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem. 2009 Nov; 55(11):1910-31. PMID: 19745062.
      Citations:    
    138. Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):24-32. PMID: 19631478.
      Citations:    
    139. Della Grotta S, LaGasse LL, Arria AM, Derauf C, Grant P, Smith LM, Shah R, Huestis M, Liu J, Lester BM. Patterns of methamphetamine use during pregnancy: results from the Infant Development, Environment, and Lifestyle (IDEAL) Study. Matern Child Health J. 2010 Jul; 14(4):519-27. PMID: 19565330.
      Citations:    
    140. Smith ML, Barnes AJ, Huestis MA. Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol. 2009 May; 33(4):185-9. PMID: 19470219.
      Citations:    
    141. Barnes AJ, De Martinis BS, Gorelick DA, Goodwin RS, Kolbrich EA, Huestis MA. Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. Clin Chem. 2009 Mar; 55(3):454-62. PMID: 19168553.
      Citations:    
    142. Goodwin RS, Darwin WD, Chiang CN, Shih M, Li SH, Huestis MA. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008 Oct; 32(8):562-9. PMID: 19007504.
      Citations:    
    143. Barnes AJ, Smith ML, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem. 2008 Jan; 54(1):172-80. PMID: 17981924.
      Citations:    
    144. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA. Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol. 2007 Oct; 31(8):477-85. PMID: 17988462.
      Citations:    
    145. Huestis MA, Darwin WD, Shimomura E, Lalani SA, Trinidad DV, Jenkins AJ, Cone EJ, Jacobs AJ, Smith ML, Paul BD. Cocaine and metabolites urinary excretion after controlled smoked administration. J Anal Toxicol. 2007 Oct; 31(8):462-8. PMID: 17988460.
      Citations:    
    146. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA. Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A. 2007 Sep 07; 1163(1-2):318-27. PMID: 17640656.
      Citations:    
    147. Shakleya DM, Jansson LM, Huestis MA. Validation of a LC-APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 01; 856(1-2):267-72. PMID: 17602899.
      Citations:    
    148. Smith ML, Vorce SP, Holler JM, Shimomura E, Magluilo J, Jacobs AJ, Huestis MA. Modern instrumental methods in forensic toxicology. J Anal Toxicol. 2007 Jun; 31(5):237-53, 8A-9A. PMID: 17579968.
      Citations:    
    149. Huestis MA, Scheidweiler KB, Saito T, Fortner N, Abraham T, Gustafson RA, Smith ML. Excretion of Delta9-tetrahydrocannabinol in sweat. Forensic Sci Int. 2008 Jan 30; 174(2-3):173-7. PMID: 17481836.
      Citations:    
    150. Lehrmann E, Colantuoni C, Deep-Soboslay A, Becker KG, Lowe R, Huestis MA, Hyde TM, Kleinman JE, Freed WJ. Transcriptional changes common to human cocaine, cannabis and phencyclidine abuse. PLoS One. 2006 Dec 27; 1:e114. PMID: 17205118.
      Citations:    
    151. Kolbrich EA, Barnes AJ, Gorelick DA, Boyd SJ, Cone EJ, Huestis MA. Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol. 2006 Oct; 30(8):501-10. PMID: 17132243.
      Citations:    
    152. Huestis MA, Gustafson RA, Moolchan ET, Barnes A, Bourland JA, Sweeney SA, Hayes EF, Carpenter PM, Smith ML. Cannabinoid concentrations in hair from documented cannabis users. Forensic Sci Int. 2007 Jul 04; 169(2-3):129-36. PMID: 16963215.
      Citations:    
    153. Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit. 2006 Aug; 28(4):545-51. PMID: 16885723.
      Citations:    
    154. Huestis MA, Elsohly M, Nebro W, Barnes A, Gustafson RA, Smith ML. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther Drug Monit. 2006 Aug; 28(4):540-4. PMID: 16885722.
      Citations:    
    155. Lowe RH, Barnes AJ, Lehrmann E, Freed WJ, Kleinman JE, Hyde TM, Herman MM, Huestis MA. A validated positive chemical ionization GC/MS method for the identification and quantification of amphetamine, opiates, cocaine, and metabolites in human postmortem brain. J Mass Spectrom. 2006 Feb; 41(2):175-84. PMID: 16382483.
      Citations:    
    156. Huestis MA, Smith ML. Modern analytical technologies for the detection of drug abuse and doping. Drug Discov Today Technol. 2006; 3(1):49-57. PMID: 24980101.
      Citations:    
    157. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA. Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict. 2006 Jan-Feb; 15(1):8-14. PMID: 16449088.
      Citations:    
    158. Paul BD, Lalani S, Bosy T, Jacobs AJ, Huestis MA. Concentration profiles of cocaine, pyrolytic methyl ecgonidine and thirteen metabolites in human blood and urine: determination by gas chromatography-mass spectrometry. Biomed Chromatogr. 2005 Nov; 19(9):677-88. PMID: 15841503.
      Citations:    
    159. Murphy CM, Huestis MA. LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-beta-D-glucuronide, morphine-6-beta-D-glucuronide, and codeine-6-beta-D-glucuronide in human urine. J Mass Spectrom. 2005 Nov; 40(11):1412-6. PMID: 16258895.
      Citations:    
    160. Huestis MA, Barnes A, Smith ML. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. Clin Chem. 2005 Dec; 51(12):2289-95. PMID: 16223887.
      Citations:    
    161. Kacinko SL, Barnes AJ, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. Clin Chem. 2005 Nov; 51(11):2085-94. PMID: 16166169.
      Citations:    
    162. Scheidweiler KB, Cone EJ, Moolchan ET, Huestis MA. Dose-related distribution of codeine, cocaine, and metabolites into human hair following controlled oral codeine and subcutaneous cocaine administration. J Pharmacol Exp Ther. 2005 May; 313(2):909-15. PMID: 15743923.
      Citations:    
    163. Huestis MA, Cone EJ. Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol. 2004 Sep; 28(6):394-9. PMID: 15516285.
      Citations:    
    164. Scheidweiler KB, Huestis MA. Simultaneous quantification of opiates, cocaine, and metabolites in hair by LC-APCI-MS/MS. Anal Chem. 2004 Aug 01; 76(15):4358-63. PMID: 15283573.
      Citations:    
    165. Saito T, Wtsadik A, Scheidweiler KB, Fortner N, Takeichi S, Huestis MA. Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem. 2004 Nov; 50(11):2083-90. PMID: 15271860.
      Citations:    
    166. Kacinko SL, Barnes AJ, Kim I, Moolchan ET, Wilson L, Cooper GA, Reid C, Baldwin D, Hand CW, Huestis MA. Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. Forensic Sci Int. 2004 Apr 20; 141(1):41-8. PMID: 15066713.
      Citations:    
    167. Gustafson RA, Kim I, Stout PR, Klette KL, George MP, Moolchan ET, Levine B, Huestis MA. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. J Anal Toxicol. 2004 Apr; 28(3):160-7. PMID: 15107145.
      Citations:    
    168. Gustafson RA, Moolchan ET, Barnes A, Levine B, Huestis MA. Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Dec 05; 798(1):145-54. PMID: 14630369.
      Citations:    
    169. Kolbrich EA, Kim I, Barnes AJ, Moolchan ET, Wilson L, Cooper GA, Reid C, Baldwin D, Hand CW, Huestis MA. Cozart RapiScan Oral Fluid Drug Testing System: an evaluation of sensitivity, specificity, and efficiency for cocaine detection compared with ELISA and GC-MS following controlled cocaine administration. J Anal Toxicol. 2003 Oct; 27(7):407-11. PMID: 14606993.
      Citations:    
    170. Barnes AJ, Kim I, Schepers R, Moolchan ET, Wilson L, Cooper G, Reid C, Hand C, Huestis MA. Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart Opiate Microplate EIA and GC-MS following controlled codeine administration. J Anal Toxicol. 2003 Oct; 27(7):402-7. PMID: 14606992.
      Citations:    
    171. Cone EJ, Sampson-Cone AH, Darwin WD, Huestis MA, Oyler JM. Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol. 2003 Oct; 27(7):386-401. PMID: 14606991.
      Citations:    
    172. Gustafson RA, Levine B, Stout PR, Klette KL, George MP, Moolchan ET, Huestis MA. Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem. 2003 Jul; 49(7):1114-24. PMID: 12816908.
      Citations:    
    173. Pope HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 2003 Apr 01; 69(3):303-10. PMID: 12633916.
      Citations:    
    174. Dams R, Murphy CM, Choo RE, Lambert WE, De Leenheer AP, Huestis MA. LC-atmospheric pressure chemical ionization-MS/ MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. Anal Chem. 2003 Feb 15; 75(4):798-804. PMID: 12622369.
      Citations:    
    Huestis's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (389)
    Explore
    _
    Similar People (60)
    Explore
    _